RxDoctor Payments Data

Mark Ruff, OD

Optometrist · Marietta, OHNPI 1831120096

Payments from drug & device makers

$1,537in general payments, 2019–2025

Across 29 payments — averaging $52.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$327
  • Genmab U.S., Inc.$240
  • Maculogix, Inc.$150
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$138
  • LKC Technologies, Inc.$120
  • Lombart Brothers, Inc.$99
  • plus $462 from 10 others

What the payments were for

  • Speaking & faculty fees$503%
  • Food & beverage$1,40491%
  • Entertainment$825%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,537 in reported general payments places this provider in the 65th percentile of 1,995 optometrist providers in Ohio.

See all optometrist providers in Ohio

Medicare billing

Part B allowed, 2024
$75,637
Medicare patients
422
Services billed
1,009

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine33$25,598
XiidraLifitegrast13$16,626
LumiganBimatoprost30$12,606
Restasis MultidoseCyclosporine19$11,797
Cyclosporine17$9,474
Brinzolamide13$3,226
Latanoprost300$2,116
Loteprednol Etabonate11$1,304
Timolol Maleate144$1,042
Brimonidine Tartrate76$665
Dorzolamide Hcl41$557
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$512
ErythromycinErythromycin Base50$503
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat28$494
Prednisolone Acetate20$420

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Restasis Multidose$13$50,00082 claims
Bausch & Lomb Americas Inc.Xiidra$39$16,62613 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$138$1,30411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,995 optometrist providers in Ohio.

Other optometrist in Marietta

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →